View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
  2. Company News
February 8, 2019

Pulmatrix to initiate Phase II trial of Pulmazole

US-based biopharmaceutical firm Pulmatrix is set to launch a Phase II clinical trial of Pulmazole (PUR1900) in the first half of this year following receipt of approval from the US Food and Drug Administration (FDA).

US-based biopharmaceutical firm Pulmatrix is set to launch a Phase II clinical trial of Pulmazole (PUR1900) in the first half of this year following receipt of approval from the US Food and Drug Administration (FDA).

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

The regulatory agency approved the associated investigational new drug (IND) application.

Pulmazole is an inhaled iSPERSE formulation of the anti-fungal drug itraconazole being developed for the treatment of allergic bronchopulmonary aspergillosis (ABPA) in asthma patients.  

iSPERSE is the company’s dry powder delivery platform designed to maximise local concentrations in order to enhance therapeutic delivery to the lungs.

The randomised, double-blind, multi-centre, placebo-controlled Phase II trial will assess the safety, tolerability, and pharmacokinetics of Pulmazole in a total of 64 adult patients.

Patients will be randomised into four arms, where 10mg, 20mg, or 35mg PUR1900 or placebo will be administered as dry powder inhalation once-a-day for 28 days.

“This is a critical step in the progression of Pulmazole to bring the product to patients in the US.”

The trail’s primary objective is the evaluation of the safety and tolerability of multiple-dose administration of Pulmazole in adult asthmatic subjects suffering from ABPA.

Secondary objectives include pharmacokinetics of multiple-dose administration of inhaled PUR1900 in plasma and sputum.

The trial will also monitor the effect of the investigational drug on relevant biomarkers of inflammation, pulmonary function (FEV1), asthma symptoms and aspergillus burden in sputum.

The company expects top-line results from the trial to be available in the second quarter of 2020.

Pulmatrix CEO Robert Clarke said: “We are very pleased that the FDA review of the IND is complete allowing us to proceed and this important regulatory milestone reinforces Pulmatrix’s intention to bring an improved novel therapeutic option to patients suffering from ABPA.

“This is a critical step in the progression of Pulmazole to bring the product to patients in the US.”

The company’s pipeline also includes a narrow spectrum kinase inhibitor called PUR1800 to treat obstructive lung diseases including asthma and chronic obstructive pulmonary disease (COPD).

Related Companies

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena